european biopharma therapeutics

What european biopharma therapeutics does

European Biopharma Therapeutics (EBT) is a specialty biopharmaceutical platform founded in 2022 in Stuttgart, Germany by Dr. Andreas Penk (CEO) and Dr. Thomas Rudolph (Executive Chairman) together with nine additional professionals bringing more than 200 years of combined large-pharma experience. The firm operates as a European commercialization partner for oncology assets, with a particular focus on rare and ultra-rare precision medicine indications. It targets three customer segments — Large & Mid-Size Pharma (offloading de-prioritized but already-registered assets), Small Biotech (launching novel assets into Europe), and Chinese Biotech (seeking European market entry and registration) — and offers flexible deal structures including acquisition, licensing, and co-promotion arrangements.

The company's service portfolio spans the full European commercialization stack: product launch planning, promotional and medical affairs, KOL engagement, supply chain distribution, pharmacovigilance, regulatory compliance, and pricing/reimbursement strategy. A US office was established in New York to support transatlantic deal sourcing. The platform layers two proprietary digital tools onto these services — OncoMind™ for navigating complex oncology networks and OncoDecide™ for access and reimbursement decision-making — and operates across Western Europe, Central & Eastern Europe, Israel, the Middle East & Africa, and Latin America, materially wider than its German legal domicile implies.

EBT is privately held (no funding rounds, parent, or subsidiaries disclosed) and reports 1–10 employees. Revenue, deal volume, and customer identity are not disclosed. Its stated go-to-market is enterprise field sales against pharma and biotech counterparties, with marketing concentrated on LinkedIn, the company website, and industry events. The combination of Big Pharma executive bench, asset-flexibility (buy / license / co-promote), and a digital overlay represents the core commercial thesis, though the scale of actual deal activity and any software revenue contribution remain unverified.

Name

european biopharma therapeutics

Legal name

European Biopharma Therapeutics EeBeTe GmbH

Website

https://ebt-pharma.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Oncology Pharmaceuticals Commercialization

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), Services-Health Services (8000)

akta.pro primary industry

Oncology Specialty Pharmaceuticals (HLAIACAA)

Keywords

• Oncology pharmaceuticals
• Pharmaceutical licensing
• Oncology commercialization
• Precision medicine oncology
• Rare cancer therapeutics

Headquarters

HQ city

Berlin

HQ country

Germany

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Licensing and Co-promotion: Flexible deal structures including licensing arrangements where EBT commercializes products on behalf of biotech and pharma companies in European markets, handling product launch, promotional activities, and commercialization support.
2. Acquisition: Acquisition of de-prioritized assets from large and mid-size pharma that are already registered in Europe or ex-Europe.
3. Co-promotion: Joint promotional arrangements with partners, sharing financial upside and leveraging digital infrastructure for partnerships on additional products.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

European Biopharma Therapeutics (EBT) is a specialty biopharmaceutical platform that commercializes oncology products across Europe on behalf of pharma and biotech partners. The company acquires, licenses, or co-promotes de-prioritized or novel oncology assets and delivers end-to-end commercialization services including launch planning, medical affairs and KOL management, supply chain distribution, pharmacovigilance, regulatory compliance, and pricing and reimbursement strategies.

Product overview

European Biopharma Therapeutics is a specialty pharmaceuticals platform focused on oncology, operating as a single integrated offering rather than a modular platform. The company combines proprietary digital tools (OncoMind™ and OncoDecide™) with comprehensive commercialization services including product launch planning, promotional/marketing activities, medical affairs and KOL management, supply chain distribution, pharmacovigilance and regulatory compliance, pricing and reimbursement strategies, and full commercialization support across Europe. The company serves large and mid-size pharma (de-prioritized assets), small biotech (novel launch assets), and Chinese biotech, targeting rare and ultra-rare oncology indications with a focus on precision medicine.

Differentiator

Problem solved

Functional benefit

Products and services

• Oncology Commercialization Services
• Asset Licensing Arrangement
• Asset Acquisition and Co-Promotion

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

One partnership is on record.

• EBT EeBeTe GmbHcoreOthersEuropean legal entity registered in Stuttgart, Germany, serving as the corporate structure for European operations and business activities.

Scale indicators6 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Medison Pharma: Israel-headquartered global pharma commercialization partner that licenses, distributes, and commercializes specialty/biotech products across Europe, CEE, Israel, and Asia-Pacific. Closely comparable to EBT in operating model, customer base (pharma/biotech seeking regional commercialization), and oncology focus.
• Swixx BioPharma: CEE and Western Europe-focused biopharma commercialization partner that represents, licenses, and distributes products on behalf of global pharma and biotech. Highly comparable to EBT given overlapping CEE/European geographic emphasis and outsourced commercialization model.
• EVERSANA: U.S.-based end-to-end commercial services provider for pharma and biotech, with strong specialty and rare-disease capabilities. Comparable to EBT in providing commercialization, market access, and distribution services, but at materially larger scale and broader scope.
• Indegene: Global commercial and medical services firm for biopharma, combining technology platforms with commercial operations support. Comparable to EBT in the digital-first commercialization tooling and oncology/life sciences customer base.
• PharmaLex (now part of Cencora): Specialized pharma services provider focused on regulatory affairs, pharmacovigilance, and market access consulting. Comparable to EBT's stated expertise in European regulatory, PV, and pricing/reimbursement, though PharmaLex is services-only with no commercialization/asset ownership.
• Syneos Health: Biopharma solutions provider spanning clinical development and commercial deployment, including contract field sales and patient access services. Comparable to EBT in the outsourced commercial execution model for pharma/biotech, though Syneos is U.S.-centric and far larger.

Broad incumbents

• IQVIA: Global biopharma services giant spanning clinical, real-world evidence, technology, and commercial services including market access and field deployment. A broad incumbent offering overlapping capabilities to EBT, but at vastly greater scale and as part of a much wider portfolio.
• Cencora (formerly AmerisourceBergen): Global pharmaceutical distribution and solutions company offering specialty distribution, commercialization, and consulting (including via PharmaLex and World Courier). Comparable to EBT in distribution and commercialization, but at massive scale across many therapeutic areas.
• STADA Arzneimittel: European specialty and generics pharmaceutical company with a strong specialty portfolio across multiple therapeutic areas including oncology. A broad incumbent with overlapping European specialty pharma footprint, but operating as a product-owning manufacturer rather than a service platform.
• Recordati: European specialty pharmaceutical group with presence in oncology, rare diseases, and other specialty areas, distributing across Europe and other regions. A broad incumbent that competes with EBT in European specialty oncology distribution, but as an integrated manufacturer-marketer rather than a service platform.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/european-biopharma-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about european biopharma therapeutics